Prostate Cancer Clinical Trials

Showing 1901-1920 of 2,150 trials

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

NCT00967954

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and tissue samples from patients with prostate cancer receiving androgen deprivation therapy.

Prostate Cancer

Cancer Research UK120 participantsStarted Sep 2008

Cambridge, England, United Kingdom

COMPLETEDPhase 1/2

Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients

NCT00433797

We will study the effect of dietary intervention in patients with prostate cancer. Outcomes include serum PSA kinetics, as well as biomarkers of inflammation, antioxidant status, oxidative stress and oxidative damage in blood cells, plasma, urine and prostate tissues

Prostate Cancer

University of Oslo86 participantsStarted Jun 2007

Oslo, Norway

UNKNOWNPhase 2

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003717

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus estramustine in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Prostate Cancer

St. Barnabas Medical Center17 participantsStarted Oct 1998

Livingston, New Jersey, United States • Long Branch, New Jersey, United States

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Related Searches

Sandostatin for Patients With Androgen Independent Prostate Cancer

Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy

Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Pilot Study on Focal Prostate Radio-Frequency Ablation

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

3-AP in Treating Patients With Advanced Prostate Cancer

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia

Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy